Today, PlasmaSelect AG has signed cooperation and supply agreements with the Indian pharmaceutical company Claris Lifesciences Ltd. According to these agreements, Claris will supply specific injectable generic drugs in addition to fat-based infusion solutions. This also Includes the anaesthetic Propofol, whose market volume in Germany alone amounts to around 45 million euros per annum.
PlasmaSelect AG will market the products in Germany and Europe. "We believe the coopera-
|
|
| -tion with our Indian partner Claris offers excellent opportunities firstly for licensing inexpensive generic products and secondly, due to Claris' technical know-how, for acquiring access to the promising Propofol market in Europe," explained COO Burghard Weldler. 'PlasmaSelect is already widely represented with its portfolio on the market for Injectable anaesthetics. Propofol constitutes the perfect complement to -this offering. We expect the new products to enter the market in late-2006." |
|
